Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia
Affiliation
Paediatric Haematology and Oncology, Tata Medical Center, Kolkata, IndiaIssue Date
2023
Metadata
Show full item recordAbstract
NoneCitation
Ghara N, Saha V. Nelarabine and optimisation of therapy for T-cell acute lymphoblastic leukaemia. The Lancet Haematology. 2023 May 8. PubMed PMID: 37167993. Epub 2023/05/12. eng.Journal
Lancet HaematologyDOI
10.1016/s2352-3026(23)00091-1PubMed ID
37167993Additional Links
https://dx.doi.org/10.1016/s2352-3026(23)00091-1Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/s2352-3026(23)00091-1
Scopus Count
Collections
Related articles
- Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
- Authors: DeAngelo DJ
- Issue date: 2009 Oct
- The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
- Authors: Miller LH, Maxa KL, Winter SS, Gossai NP
- Issue date: 2023 Jul-Dec
- Nelarabine-containing salvage therapy and conditioning regimen in transplants for pediatric T-cell acute lymphoblastic leukemia and lymphoma.
- Authors: Yanagi M, Mori M, Honda M, Mitani Y, Seki M, Fukuoka K, Oshima K, Arakawa Y, Koh K
- Issue date: 2024 Mar
- The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience.
- Authors: Dyakonova YY, Bydanov OI, Popov AM, Olshanskaya YV, Boichenko EG, Aleynikova OV, Maschan MA, Shelikhova LN, Litvinov DV, Khachatryan LA, Ponomareva NI, Fechina LG, Novichkova GA, Pashanov ED, Karachunskiy AI
- Issue date: 2018 Aug 17
- Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
- Authors: Sripornsawan P, Okamoto Y, Nishikawa T, Kodama Y, Yamaki Y, Kurauchi K, Tanabe T, Nakagawa S, Shinkoda Y, Imuta N, Kawano Y
- Issue date: 2017 Feb